DE1803492A1 - Neue therapeutische Kombination - Google Patents
Neue therapeutische KombinationInfo
- Publication number
- DE1803492A1 DE1803492A1 DE19681803492 DE1803492A DE1803492A1 DE 1803492 A1 DE1803492 A1 DE 1803492A1 DE 19681803492 DE19681803492 DE 19681803492 DE 1803492 A DE1803492 A DE 1803492A DE 1803492 A1 DE1803492 A1 DE 1803492A1
- Authority
- DE
- Germany
- Prior art keywords
- spi
- tumor
- dpm
- bradykinin
- series
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001225 therapeutic effect Effects 0.000 title claims description 10
- 239000000824 cytostatic agent Substances 0.000 claims description 22
- 101800004538 Bradykinin Proteins 0.000 claims description 21
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 claims description 21
- 102100035792 Kininogen-1 Human genes 0.000 claims description 21
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 claims description 21
- 230000001085 cytostatic effect Effects 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 5
- CPTIBDHUFVHUJK-NZYDNVMFSA-N mitopodozide Chemical compound C1([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H](CO)[C@@H]2C(=O)NNCC)=CC(OC)=C(OC)C(OC)=C1 CPTIBDHUFVHUJK-NZYDNVMFSA-N 0.000 claims description 4
- 102000007562 Serum Albumin Human genes 0.000 claims description 3
- 108010071390 Serum Albumin Proteins 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 description 38
- 210000002751 lymph Anatomy 0.000 description 21
- 230000000694 effects Effects 0.000 description 17
- 238000001802 infusion Methods 0.000 description 15
- 239000000243 solution Substances 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- 210000002414 leg Anatomy 0.000 description 10
- 241000282472 Canis lupus familiaris Species 0.000 description 8
- 239000003708 ampul Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000036765 blood level Effects 0.000 description 5
- NOVZFMNCTCKLPF-UHFFFAOYSA-N 2,5-bis(aziridin-1-yl)-3,6-dipropoxycyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C(OCCC)=C(N2CC2)C(=O)C(OCCC)=C1N1CC1 NOVZFMNCTCKLPF-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010093008 Kinins Proteins 0.000 description 3
- 102000002397 Kinins Human genes 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000036770 blood supply Effects 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229910052722 tritium Inorganic materials 0.000 description 3
- MFJCORKPUUOBMV-UHFFFAOYSA-N 1,1,2-trichloro-2-methylpropan-1-ol Chemical compound CC(C)(Cl)C(O)(Cl)Cl MFJCORKPUUOBMV-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 230000002927 anti-mitotic effect Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 210000004324 lymphatic system Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- XRBSKUSTLXISAB-XVVDYKMHSA-N (5r,6r,7r,8r)-8-hydroxy-7-(hydroxymethyl)-5-(3,4,5-trimethoxyphenyl)-5,6,7,8-tetrahydrobenzo[f][1,3]benzodioxole-6-carboxylic acid Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H](CO)[C@@H]2C(O)=O)=C1 XRBSKUSTLXISAB-XVVDYKMHSA-N 0.000 description 1
- XRBSKUSTLXISAB-UHFFFAOYSA-N (7R,7'R,8R,8'R)-form-Podophyllic acid Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C(CO)C2C(O)=O)=C1 XRBSKUSTLXISAB-UHFFFAOYSA-N 0.000 description 1
- NJESAXZANHETJV-UHFFFAOYSA-N 4-methylsalicylic acid Chemical compound CC1=CC=C(C(O)=O)C(O)=C1 NJESAXZANHETJV-UHFFFAOYSA-N 0.000 description 1
- 101100493820 Caenorhabditis elegans best-1 gene Proteins 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 108010003195 Kallidin Proteins 0.000 description 1
- FYSKZKQBTVLYEQ-FSLKYBNLSA-N Kallidin Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CCC1 FYSKZKQBTVLYEQ-FSLKYBNLSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241000287181 Sturnus vulgaris Species 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004049 embossing Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 210000003090 iliac artery Anatomy 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- TVDSBUOJIPERQY-UHFFFAOYSA-N prop-2-yn-1-ol Chemical compound OCC#C TVDSBUOJIPERQY-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/043—Kallidins; Bradykinins; Related peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH1472767 | 1967-10-20 | ||
| CH289468 | 1968-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE1803492A1 true DE1803492A1 (de) | 1969-06-26 |
Family
ID=25691663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19681803492 Pending DE1803492A1 (de) | 1967-10-20 | 1968-10-17 | Neue therapeutische Kombination |
Country Status (5)
| Country | Link |
|---|---|
| BE (1) | BE722587A (cs) |
| DE (1) | DE1803492A1 (cs) |
| FR (1) | FR7979M (cs) |
| GB (1) | GB1246315A (cs) |
| SE (1) | SE352533B (cs) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992018529A1 (en) * | 1991-04-23 | 1992-10-29 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2657381C2 (de) * | 1976-12-17 | 1982-03-25 | Thera Gesellschaft für Patentverwertung mbH, 8036 Herrsching | Glucosehaltige Infusionslösung |
| US5112596A (en) * | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
-
1968
- 1968-09-30 SE SE1318268A patent/SE352533B/xx unknown
- 1968-10-16 FR FR170109A patent/FR7979M/fr not_active Expired
- 1968-10-17 DE DE19681803492 patent/DE1803492A1/de active Pending
- 1968-10-18 BE BE722587D patent/BE722587A/xx unknown
- 1968-10-18 GB GB49497/68A patent/GB1246315A/en not_active Expired
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5506206A (en) * | 1990-04-23 | 1996-04-09 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| WO1992018529A1 (en) * | 1991-04-23 | 1992-10-29 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| US5686416A (en) * | 1991-04-23 | 1997-11-11 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| EP0885900A3 (en) * | 1991-04-23 | 2000-04-26 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptide derivatives of bradykinin |
Also Published As
| Publication number | Publication date |
|---|---|
| SE352533B (cs) | 1973-01-08 |
| BE722587A (cs) | 1969-04-18 |
| FR7979M (cs) | 1970-06-08 |
| GB1246315A (en) | 1971-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69822665T2 (de) | Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen | |
| DE60103453T2 (de) | Verwendung von albuminstabilisiertem Paclitaxel zur Herstellung eines Arzneimittels zum Behandeln von festen Tumoren und das so erhaltene Arzneimittel | |
| DE60117711T2 (de) | Antineoplastisches arzneimittel | |
| DE3751761T2 (de) | Penetrationsverbesserer für die transdermale Verabreichung von systemisch wirksamen Arzneimitteln | |
| EP0065747B1 (de) | Nonapeptid zur Behandlung von Suchtmittelentzugserscheinungen | |
| DE1902227A1 (de) | Arzneimittel zur psychotherapeutischen Anwendung und Verfahren zu seiner Herstellung | |
| EP0722719B1 (de) | Verfahren zur Herstellung von Flavano-Lignan-Zubereitungen | |
| DE69024053T2 (de) | Behandlung zur ermässigung von ödem und muskelschäden. | |
| EP0185210A2 (de) | Verwendung von Dipeptidderivaten für die Herstellung von Arzneimitteln zur Behandlung von an amyotropher Lateralsklerose Erkrankten | |
| DE69213757T2 (de) | Verwendung von kreatinphosphat oder phosphoenolbrenztraubensäure zur behandlung von tumoren | |
| DE1915798C3 (de) | Antacidum-Präparat in Form einer wäßrigen Suspension | |
| DE69813070T2 (de) | Pharmazeutische Zubereitung zur oralen Anwendung enthaltend einen Histamin-Immunoglobulin Komplex | |
| DE1803492A1 (de) | Neue therapeutische Kombination | |
| Elliot et al. | The pharmacologic properties of an insulin-free extract of pancreas and the circulatory hormone of Frey | |
| DE10228680A1 (de) | Grundlage für transdermale Formulierungen (PTF) | |
| DE2131679A1 (de) | 3,4,5-Trimethoxybenzamidocarbonsaeure und ihre Salze sowie Arzneipraeparate | |
| DE2349186C2 (de) | Arzneimittel zur Verbesserung der Zellatmung, der Herzmuskelleistung und der Hirnfunktion | |
| DE3621036A1 (de) | Fluessige ibuprofen-zubereitungen | |
| DE2110537C3 (de) | N-Pyridyl-brenzschleimsäureamide, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel | |
| DE3519736C2 (de) | Mittel zur Behandlung von Rheuma und Polyarthritis | |
| DE3023396C2 (de) | Arzneimittel zur intravenösen Krebstherapie | |
| DE2055930A1 (de) | Verbesserte orale Applikationsform von Raubasin | |
| DE10238161A1 (de) | Mineralstoff-Ampulle für die mucosale und topische Wirkstoffapplikation | |
| EP0210295B1 (de) | Arzneimittel zur Behandlung chronisch entzündlicher Darmerkrankungen | |
| DE4309339A1 (de) | Biologisch aktives pharmazeutisches Präparat |